Accession NoReference
001DEThe effect of genetic polymorphisms in CYP2C9 on sulphamethoxazole N-hydroxylation.Gill HJ, Tjia JF, Kitteringham NR, Pirmohamed M, Back DJ, Park BK.Pharmacogenetics. 1999 Feb;9(1):43-53.
002DE.Antitumor activity of methoxymorpholinyl doxorubicin: potentiation by cytochrome P450 3A metabolism.Lu H, Waxman DJ.Mol Pharmacol. 2005 Jan;67(1):212-9. Epub 2004 Oct 1.
003DE.Influence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes.Glaeser H, Drescher S, Eichelbaum M, Fromm MF.Br J Clin Pharmacol. 2005 Feb;59(2):199-206.
004DETherapeutic impact of CYP2C19 pharmacogenetics on proton pump inhibitor-based eradication therapy for Helicobacter pylori Methods Find Exp.Furuta T, Shirai N, Ohashi K, Ishizaki T. Clin Pharmacol. 2003 Mar;25(2):131-43
005DELipophilic antifolate trimetrexate is a potent inhibitor of Trypanosoma cruzi: prospect for chemotherapy of Chagas' disease.Senkovich O, Bhatia V, Garg N, Chattopadhyay D.Antimicrob Agents Chemother. 2005 Aug;49(8):3234-8
006DEViral delivery of P450 reductase recapitulates the ability of constitutive overexpression of reductase enzymes to potentiate the activity of mitomycin C in human breast cancer xenografts.Cowen RL, Patterson AV, Telfer BA, Airley RE, Hobbs S, Phillips RM, Jaffar M, Stratford IJ, Williams KJ.Mol Cancer Ther. 2003 Sep;2(9):901-9.
007DEScreening for inhibitory effects of antineoplastic agents on CYP3A4 in human liver microsomes.Baumhakel M, Kasel D, Rao-Schymanski RA, Bocker R, Beckurts KT, Zaigler M, Barthold D, Fuhr U.Int J Clin Pharmacol Ther. 2001 Dec;39(12):517-28.
008DEA molecular epidemiology study in women from Upper Silesia, Poland.Toxicol Lett. Motykiewicz G, Michalska J, Pendzich J, Malusecka E, Strozyk M, Kalinowska E, Butkiewicz D, Mielzynska D, Midro A, Santella RM, Chorazy M.1998 Aug;96-97:195-202
009DEMetabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions.Decker CJ, Laitinen LM, Bridson GW, Raybuck SA, Tung RD, Chaturvedi PR.J Pharm Sci. 1998 Jul;87(7):803-7.
010DEStudies on the efficient syntheses of the drug metabolites.Otsubo K. Yakugaku Zasshi. 2000 Nov;120(11):1135-47.
011DEDifferent effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status.Uno T, Shimizu M, Yasui-Furukori N, Sugawara K, Tateishi T.
012DETramadol disposition in the very young: an attempt to assess in vivo cytochrome P-450 2D6 activity.Allegaert K, Anderson BJ, Verbesselt R, Debeer A, de Hoon J, Devlieger H, Van Den Anker JN, Tibboel D.Br J Anaesth. 2005 Aug;95(2):231-9. Epub 2005 Jun 10.
013DEIn vitro inhibition of a polymorphic human liver P-450 isozyme by narcotic analgesics.Henthorn TK, Spina E, Dumont E, von Bahr C.Anesthesiology. 1989 Feb;70(2):339-42.
014DECodeine intoxication associated with ultrarapid CYP2D6 metabolism.Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J.N Engl J Med. 2004 Dec 30;351(27):2827-31
015DEMelperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine.Grozinger M, Dragicevic A, Hiemke C, Shams M, Muller MJ, Hartter S.Pharmacopsychiatry. 2003 Jan;36(1):3-6.
016DECiprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism.Granfors MT, Backman JT, Neuvonen M, Neuvonen PJ.Clin Pharmacol Ther. 2004 Dec;76(6):598-606.
017DEPharmacogenetics of antihypertensive drug responses.Schwartz GL, Turner ST.Am J Pharmacogenomics. 2004;4(3):151-60.
018DEMetabolism of psychotropic drugs: pharmacological and clinical relevance.Daniel W.Pol J Pharmacol. 1995 Sep-Oct;47(5):367-79
019DEModulation of Acetaminophen-Induced Hepatotoxicity by the Xenobiotic Receptor CAR.Zhang J, Huang W, Chua SS, Wei P, Moore DD.Science. 2002 Oct 11;298(5592):422-4
020DEImpact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting.Grasmader K, Verwohlt PL, Rietschel M, Dragicevic A, Muller M, Hiemke C, Freymann N, Zobel A, Maier W, Rao ML.Eur J Clin Pharmacol. 2004 Jul;60(5):329-36. Epub 2004 May 28.
021DEIdentification and differentiation of barbiturates, other sedative-hypnotics and their metabolites in urine integrated in a general screening procedure using computerized gas chromatography-mass spectrometry.Maurer HH.J Chromatogr. 1990 Sep 14;530(2):307-26.
022DEPharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases.Jin M, Gock SB, Jannetto PJ, Jentzen JM, Wong SH.J Anal Toxicol. 2005 Oct;29(7):590-8.
023DEMolecular basis of the low activity of antitumor anthracenediones, mitoxantrone and ametantrone, in oxygen radical generation catalyzed by NADH dehydrogenase. Enzymatic and molecular modelling studies.Tarasiuk J, Mazerski J, Tkaczyk-Gobis K, Borowski E.Eur J Med Chem. 2005 Apr;40(4):321-8. Epub 2004 Dec 15.
024DEDrug interactions in dentistry: the importance of knowing your CYPs.Hersh EV, Moore PA.J Am Dent Assoc. 2004 Mar;135(3):298-311.
025DEQuantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes.Lalovic B, Phillips B, Risler LL, Howald W, Shen DD.Drug Metab Dispos. 2004 Apr;32(4):447-54.
026DEHuman CYP3A4 and the metabolism of nefaodone and hydroxynefazodone by human liver microsomes and heterologously expressed enzymes.Rotzinger S, Baker GB.Eur Neuropsychopharmacol. 2002 Apr;12(2):91-100.
027DECharacterization of the cytochrome P-450 gene family responsible for the N-dealkylation of the ergot alkaloid CQA 206-291 in humans.Ball SE, Maurer G, Zollinger M, Ladona M, Vickers AE.Drug Metab Dispos. 1992 Jan-Feb;20(1):56-63. Pharmacogenetics 11:447-458(2001).Eiselt R, Domanski TL, Zibat A, Mueller R, Presecan-Siedel E, Hustert E, Zanger UM, Brockmoller J, Klenk HP, Meyer UA, Khan KK, He YA, Halpert JR, Wojnowski L.
028DEStereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19.Gerber JG, Rhodes RJ, Gal J.Chirality. 2004 Jan;16(1):36-44.
029DEMetabolism of Meloxicam in human liver involves cytochromes P4502C9 and 3A4.Chesne C, Guyomard C, Guillouzo A, Schmid J, Ludwig E, Sauter T.Xenobiotica. 1998 Jan;28(1):1-13.
030DEPhenotype/genotype relationships for the cytochrome P450 enzyme CYP2D6 in rheumatoid arthritis: influence of drug therapy and disease activity.Beyeler C, Daly AK, Armstrong M, Astbury C, Bird HA, Idle JR.J Rheumatol. 1994 Jun;21(6):1034-9.
031DEMetabolism and elimination of quinine in healthy volunteers.Mirghani RA, Hellgren U, Bertilsson L, Gustafsson LL, Ericsson O.Eur J Clin Pharmacol. 2003 Sep;59(5-6):423-7. Epub 2003 Aug 12.
032DEEffect of aging on hepatic elimination of cimetidine and subsequent interaction of aging and cimetidine on aminopyrine metabolism.Henderson GI, Speeg KV Jr, Roberts RK, Perez A, Schenker S.Biochem Pharmacol. 1988 Jul 1;37(13):2667-73.
033DECYP3A4 is a major isoform responsible for oxidation of 7-hydroxy-Delta(8)-tetrahydrocannabinol to 7-oxo-delta(8)-tetrahydrocannabinol in human liver microsomes.Matsunaga T, Kishi N, Higuchi S, Watanabe K, Ohshima T, Yamamoto I.Drug Metab Dispos. 2000 Nov;28(11):1291-6.
034DECYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.Hutchinson MR, Menelaou A, Foster DJ, Coller JK, Somogyi AA.Br J Clin Pharmacol. 2004 Mar;57(3):287-97.
035DEThe effect of CYP2D6 polymorphisms on dextromethorphan metabolism in Mexican Americans.Casner PR.J Clin Pharmacol. 2005 Nov;45(11):1230-5.
036DEInteraction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro.Zhang W, Ramamoorthy Y, Tyndale RF, Sellers EM.Drug Metab Dispos. 2003 Jun;31(6):768-72.
037DEOxidation of caffeine by CYP1A2: isotope effects and metabolic switching.Regal KA, Kunze KL, Peter RM, Nelson SD.Drug Metab Dispos. 2005 Dec;33(12):1837-44. Epub 2005 Aug 31
038DEModulation of cytochrome P450 metabolism by ergonovine and dihydroergotamine.Moubarak AS, Rosenkrans CF Jr, Johnson ZB.Vet Hum Toxicol. 2003 Feb;45(1):6-9.
039DEMetabolism of alfentanil by cytochrome p4503a (cyp3a) enzymes.Klees TM, Sheffels P, Dale O, Kharasch ED.Drug Metab Dispos. 2005 Mar;33(3):303-11. Epub 2004 Nov 22.
040DEKetoconazole, a cytochrome P450 3A4 inhibitor, markedly increases concentrations of levo-acetyl-alpha-methadol in opioid-naive individuals.Moody DE, Walsh SL, Rollins DE, Neff JA, Huang W.Clin Pharmacol Ther. 2004 Aug;76(2):154-66.
041DEMinimal in vivo activation of CYP2C9-mediated flurbiprofen metabolism by dapsone.Hutzler JM, Frye RF, Korzekwa KR, Branch RA, Huang SM, Tracy TS.Eur J Pharm Sci. 2001 Aug;14(1):47-52.
042DERole of individual human cytochrome P450 enzymes in the in vitro metabolism of hydromorphone.Benetton SA, Borges VM, Chang TK, McErlane KM.Xenobiotica. 2004 Apr;34(4):335-44.
043DEFunctional characterization of four allelic variants of human cytochrome P450 1A2.Zhou H, Josephy PD, Kim D, Guengerich FP.Arch Biochem Biophys. 2004 Feb 1;422(1):23-30.
044DEChlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism.Shon JH, Yoon YR, Kim MJ, Kim KA, Lim YC, Liu KH, Shin DH, Lee CH, Cha IJ, Shin JG.Br J Clin Pharmacol. 2005 May;59(5):552-63.
045DEInhibitory effect of glyburide on human cytochrome p450 isoforms in human liver microsomes.Kim KA, Park JY.Drug Metab Dispos. 2003 Sep;31(9):1090-2.
046DECYP2C19 participates in tolbutamide hydroxylation by human liver microsomes.Wester MR, Lasker JM, Johnson EF, Raucy JL.Drug Metab Dispos. 2000 Mar;28(3):354-9
047DEPharmacokinetics of glimepiride and cytochrome P450 2C9 genetic polymorphisms.Wang R, Chen K, Wen SY, Li J, Wang SQ.Clin Pharmacol Ther. 2005 Jul;78(1):90-2.
048DECharacterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone.Baldwin SJ, Clarke SE, Chenery RJ. Br J Clin Pharmacol. 1999 Sep;48(3):424-32
049DEEffect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.Kirchheiner J, Roots I, Goldammer M, Rosenkranz B, Brockmoller J.Clin Pharmacokinet. 2005;44(12):1209-25.
050DEMetabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.Kajosaari LI, Laitila J, Neuvonen PJ, Backman JT.Basic Clin Pharmacol Toxicol. 2005 Oct;97(4):249-56.
051DEA three-dimensional molecular template for substrates of human cytochrome P450 involved in debrisoquine 4-hydroxylation.Islam SA, Wolf CR, Lennard MS, Sternberg MJ.Carcinogenesis. 1991 Dec;12(12):2211-9.
052DEPharmacokinetics and metabolism of nateglinide in humans.Weaver ML, Orwig BA, Rodriguez LC, Graham ED, Chin JA, Shapiro MJ, McLeod JF, Mangold JB.Drug Metab Dispos. 2001 Apr;29(4 Pt 1):415-21.
053DEEffects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone.Jaakkola T, Backman JT, Neuvonen M, Neuvonen PJ.Clin Pharmacol Ther. 2005 May;77(5):404-14.
054DEGenetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo.Ufer M, Kammerer B, Kahlich R, Kirchheiner J, Yasar U, Brockmoller J, Rane A.Xenobiotica. 2004 Sep;34(9):847-59.
055DECytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant.Sanchez RI, Wang RW, Newton DJ, Bakhtiar R, Lu P, Chiu SH, Evans DC, Huskey SE.Drug Metab Dispos. 2004 Nov;32(11):1287-92. Epub 2004 Aug 10.
056DEThe metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin.Clarke TA, Waskell LA.Drug Metab Dispos. 2003 Jan;31(1):53-9.
057DEMetabolic characterization of the major human small intestinal cytochrome p450s.Obach RS, Zhang QY, Dunbar D, Kaminsky LS.Drug Metab Dispos. 2001 Mar;29(3):347-52.
058DEPharmacokinetics and metabolism of guanfacine in man: a review.Kiechel JR. Br J Clin Pharmacol. 1980;10 Suppl 1:25S-32S.
059DEPharmacogenetics of antihypertensive drug responses.Schwartz GL, Turner ST.Am J Pharmacogenomics. 2004;4(3):151-60.
060DEClinical pharmacology of bosentan, a dual endothelin receptor antagonist.Dingemanse J, van Giersbergen PL.Clin Pharmacokinet. 2004;43(15):1089-115.
061DECYP2C9 polymorphisms and the interindividual variability in pharmacokinetics and pharmacodynamics of the loop diuretic drug torsemide.Vormfelde SV, Engelhardt S, Zirk A, Meineke I, Tuchen F, Kirchheiner J, Brockmoller J.Clin Pharmacol Ther. 2004 Dec;76(6):557-66
062DEInvolvement of CYP3A in the metabolism of eplerenone in humans and dogs: differential metabolism by CYP3A4 and CYP3A5.Cook CS, Berry LM, Kim DH, Burton EG, Hribar JD, Zhang L.Drug Metab Dispos. 2002 Dec;30(12):1344-51.
063DEBiotransformation of fluticasone: in vitro characterization.Pearce RE, Leeder JS, Kearns GL.Drug Metab Dispos. 2006 Jun;34(6):1035-40. Epub 2006 Mar 24.
064DEIn vitro metabolism and interaction of cilostazol with human hepatic cytochrome P450 isoforms.Abbas R, Chow CP, Browder NJ, Thacker D, Bramer SL, Fu CJ, Forbes W, Odomi M, Flockhart DA.Hum Exp Toxicol. 2000 Mar;19(3):178-84
065DEInvolvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans.Bottiger Y, Dostert P, Benedetti MS, Bani M, Fiorentini F, Casati M, Poggesti I, Alm C, Alvan G, Bertilsson L.Br J Clin Pharmacol. 1996 Dec;42(6):707-11
066DEInduction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor.Usui T, Saitoh Y, Komada F.Biol Pharm Bull. 2003 Apr;26(4):510-7
067DECytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function.Orlando R, Piccoli P, De Martin S, Padrini R, Floreani M, Palatini P.Clin Pharmacol Ther. 2004 Jan;75(1):80-8
068DEEffect of betamethasone on neuropathic pain and cerebral expression of NF-kappaB and cytokines.Xie W, Liu X, Xuan H, Luo S, Zhao X, Zhou Z, Xu J.Neurosci Lett. 2006 Jan 30;393(2-3):255-9. Epub 2005 Oct 25
069DEIn vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone.McCune JS, Hawke RL, LeCluyse EL, Gillenwater HH, Hamilton G, Ritchie J, Lindley C.Clin Pharmacol Ther. 2000 Oct;68(4):356-66
070DEAlcohol consumption and cancer of the gastrointestinal tract.Seitz HK, Maurer B, Stickel F.Dig Dis. 2005;23(3-4):297-303
071DEExperimental study of the excretion of urinary steroids in a group of children after topical use of flumethasone pivalate.Ormea F, Muscardin L, Gargovich G.Minerva Dermatol. 1967 Dec;42(12):624-5
072DEPharmacokinetics of flunisolide administered via metered dose inhaler with and without a spacer device and following oral administration.Dickens GR, Wermeling DP, Matheny CJ, John W, Abramowitz W, Sista SM, Foster T, Choudhury S. Ann Allergy Asthma Immunol. 2000 May;84(5):528-32.
073DEEffect of concentration and degree of saturation of topical fluocinonide formulations on in vitro membrane transport and in vivo availability on human skin.Schwarb FP, Imanidis G, Smith EW, Haigh JM, Surber C.Pharm Res. 1999 Jun;16(6):909-15
074DEEffects of lodoxamide, disodium cromoglycate and fluorometholone on tear leukotriene levels in vernal keratoconjunctivitis.Akman A, Irkec M, Orhan M.Eye. 1998;12 ( Pt 2):291-5
075DEOn the topical use of a new pharmacological association of enzymes, neomycin and hydrocortamate. Clinical contribution.Agati R, Papalia L.Minerva Dermatol. 1965 Nov;40(11):443-7
076DEAutomated on-line SPE LC-MS/MS method to quantitate 6beta-hydroxycortisol and cortisol in human urine: use of the 6beta-hydroxycortisol to cortisol ratio as an indicator of CYP3A4 activity.Barrett YC, Akinsanya B, Chang SY, Vesterqvist O. J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Jul 25;821(2):159-65
077DEIn vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol.Oldham HG, Clarke SE.Drug Metab Dispos. 1997 Aug;25(8):970-7
078DEGenetic polymorphisms in drug metabolizing enzymes--impact on treatment with beta-blockers.Wuttke H, Rau T, Eschenhagen T.Dtsch Med Wochenschr. 2004 Apr 8;129(15):831-5.
079DECYP1A2 and CYP2D6 4-hydroxylate propranolol and both reactions exhibit racial differences.Johnson JA, Herring VL, Wolfe MS, Relling MV.J Pharmacol Exp Ther. 2000 Sep;294(3):1099-105
080DEMetabolism of carteolol by cDNA-expressed human cytochrome P450.Kudo S, Uchida M, Odomi M.Eur J Clin Pharmacol. 1997;52(6):479-85
081DEInfluence of CYP2D6 genotype on metoprolol plasma concentration and beta-adrenergic inhibition during long-term treatment: a comparison with bisoprolol.Nozawa T, Taguchi M, Tahara K, Hashimoto Y, Igarashi N, Nonomura M, Kato B, Igawa A, Inoue H.J Cardiovasc Pharmacol. 2005 Nov;46(5):713-20
082DEPolymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study.Nieminen T, Uusitalo H, Maenpaa J, Turjanmaa V, Rane A, Lundgren S, Ropo A, Rontu R, Lehtimaki T, Kahonen M.Eur J Clin Pharmacol. 2005 Dec;61(11):811-9. Epub 2005 Nov 17
083DEPharmacokinetics and metabolism of bisoprolol enantiomers in humans.Horikiri Y, Suzuki T, Mizobe M.J Pharm Sci. 1998 Mar;87(3):289-94.
084DEPindolol augmentation of antidepressant response.Artigas F, Adell A, Celada P.Curr Drug Targets. 2006 Feb;7(2):139-47
085DEHigh-throughput screening to estimate single or multiple enzymes involved in drug metabolism: microtitre plate assay using a combination of recombinant CYP2D6 and human liver microsomes.Yamamoto T, Suzuki A, Kohno Y.Xenobiotica. 2003 Aug;33(8):823-39.
086DESimultaneous determination of thirteen beta-blockers and one metabolite by gradient high-performance liquid chromatography with photodiode-array UV detection.Delamoye M, Duverneuil C, Paraire F, de Mazancourt P, Alvarez JC.Forensic Sci Int. 2004 Apr 20;141(1):23-31
087DEInhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes.Nakamura K, Ariyoshi N, Iwatsubo T, Fukunaga Y, Higuchi S, Itoh K, Shimada N, Nagashima K, Yokoi T, Yamamoto K, Horiuchi R, Kamataki T. Biol Pharm Bull. 2005 May;28(5):882-5
088DEPolymorphic hydroxylation of perhexiline in vitro.Sorensen LB, Sorensen RN, Miners JO, Somogyi AA, Grgurinovich N, Birkett DJ.Br J Clin Pharmacol. 2003 Jun;55(6):635-8.
089DEInteraction potential of lercanidipine, a new vasoselective dihydropyridine calcium antagonist.Klotz U.Arzneimittelforschung. 2002;52(3):155-61
090DECalcium channel modulators of the dihydropyridine family are human pregnane X receptor activators and inducers of CYP3A, CYP2B, and CYP2C in human hepatocytes.Drocourt L, Pascussi JM, Assenat E, Fabre JM, Maurel P, Vilarem MJ.Drug Metab Dispos. 2001 Oct;29(10):1325-31
091DEIdentification of P450 enzymes involved in metabolism of verapamil in humans.Kroemer HK, Gautier JC, Beaune P, Henderson C, Wolf CR, Eichelbaum M.Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7
092DEA furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction.Paine MF, Widmer WW, Hart HL, Pusek SN, Beavers KL, Criss AB, Brown SS, Thomas BF, Watkins PB.Am J Clin Nutr. 2006 May;83(5):1097-105
093DEInteractions between grapefruit juice and cardiovascular drugs.Bailey DG, Dresser GK. Am J Cardiovasc Drugs. 2004;4(5):281-97.
094DEPrediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition.Galetin A, Burt H, Gibbons L, Houston JB.Drug Metab Dispos. 2006 Jan;34(1):166-75. Epub 2005 Oct 12
095DEInteraction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension.Nishio S, Watanabe H, Kosuge K, Uchida S, Hayashi H, Ohashi K.Hypertens Res. 2005 Mar;28(3):223-7
096DEIntestinal and hepatic metabolic activity of five cytochrome P450 enzymes - impact on prediction of first- pass metabolism.Galetin A, Houston JB.J Pharmacol Exp Ther. 2006 Jun 8.
097DEDrug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance.Fuhr U.Drug Saf. 1998 Apr;18(4):251-72.
098DEDynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus.Marques MP, Coelho EB, Dos Santos NA, Geleilete TJ, Lanchote VL.Eur J Clin Pharmacol. 2002 Dec;58(9):607-14. Epub 2002 Nov 16.
099DEDrug interactions with cisapride: clinical implications.Michalets EL, Williams CR.Clin Pharmacokinet. 2000 Jul;39(1):49-75.
100DEEffects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin.Ando H, Tsuruoka S, Yanagihara H, Sugimoto K, Miyata M, Yamazoe Y, Takamura T, Kaneko S, Fujimura A.Br J Clin Pharmacol. 2005 Nov;60(5):494-7.
101DE Clearance rates of cerivastatin metabolites in a patient with cerivastatin-induced rhabdomyolysis.Ozaki H, Ishikawa CT, Ishii T, Toyoda A, Murano T, Miyashita Y, Shirai K.J Clin Pharm Ther. 2005 Apr;30(2):189-92
102DEStudies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects.Jerling M, Huan BL, Leung K, Chu N, Abdallah H, Hussein Z.
103DEMechanistic studies on metabolic interactions between gemfibrozil and statins.Prueksaritanont T, Zhao JJ, Ma B, Roadcap BA, Tang C, Qiu Y, Liu L, Lin JH, Pearson PG, Baillie TA.J Pharmacol Exp Ther. 2002 Jun;301(3):1042-51.
104DEIn vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors.Transon C, Leemann T, Dayer P.Eur J Clin Pharmacol. 1996;50(3):209-15.
105DEClinical consequences of cytochrome P450 2C9 polymorphisms.Kirchheiner J, Brockmoller J.Clin Pharmacol Ther. 2005 Jan;77(1):1-16.
106DEEqually potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes.Cohen LH, van Leeuwen RE, van Thiel GC, van Pelt JF, Yap SH.Biopharm Drug Dispos. 2000 Dec;21(9):353-64.
107DEClinical pharmacokinetics of fibric acid derivatives (fibrates).Miller DB, Spence JD.Clin Pharmacokinet. 1998 Feb;34(2):155-62.
108DEInhibition mechanism of reconstituted cytochrome P-450scc-linked monooxygenase system by antimycotic reagents and other inhibitors.Kurokohchi K, Nishioka M, Ichikawa Y.J Steroid Biochem Mol Biol. 1992 May;42(3-4):287-92.
109DEEffect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes.Niwa T, Shiraga T, Takagi A.Biol Pharm Bull. 2005 Sep;28(9):1805-8
110DEEffects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics.Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB.Br J Clin Pharmacol. 2006 Jan;61(1):58-69.
111DECharacterization of the P450 monooxygenase NysL, responsible for C-10 hydroxylation during biosynthesis of the polyene macrolide antibiotic nystatin in Streptomyces noursei.Volokhan O, Sletta H, Ellingsen TE, Zotchev SB.Appl Environ Microbiol. 2006 Apr;72(4):2514-9.
112DEIsoforms of cytochrome P450 on organic nitrate-derived nitric oxide release in human heart vessels.Minamiyama Y, Takemura S, Akiyama T, Imaoka S, Inoue M, Funae Y, Okada S.FEBS Lett. 1999 Jun 11;452(3):165-9.
113DECYP2D6 is the principal cytochrome P450 responsible for metabolism of the histamine H1 antagonist promethazine in human liver microsomes.Nakamura K, Yokoi T, Inoue K, Shimada N, Ohashi N, Kume T, Kamataki T. Pharmacogenetics. 1996 Oct;6(5):449-57.
114DEExpression of VDR and CYP24A1 mRNA in human tumors.Anderson MG, Nakane M, Ruan X, Kroeger PE, Wu-Wong JR.Cancer Chemother Pharmacol. 2006 Jan;57(2):234-40. Epub 2005 Sep 23.
115DEStudy on the influence of silymarin pretreatment on metabolism and disposition of metronidazole.Rajnarayana K, Reddy MS, Vidyasagar J, Krishna DR.Arzneimittelforschung. 2004;54(2):109-13.
116DEBiotransformation of fluticasone: in vitro characterization.Pearce RE, Leeder JS, Kearns GL.Drug Metab Dispos. 2006 Jun;34(6):1035-40. Epub 2006 Mar 24.
117DEMetabolism of mometasone furoate and biological activity of the metabolites. * Sahasranaman S, * Issar M, * Hochhaus G. Drug Metab Dispos. 2006 Feb;34(2):225-33. Epub 2005 Oct 26
118DEEffect of methylprednisolone on CYP3A4-mediated drug metabolism in vivo. * Villikka K, * Varis T, * Backman JT, * Neuvonen PJ, * Kivisto KT. Eur J Clin Pharmacol. 2001 Sep;57(6-7):457-60.
119DEPlasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole. * Raaska K, * Niemi M, * Neuvonen M, * Neuvonen PJ, * Kivisto KT. Clin Pharmacol Ther. 2002 Oct;72(4):362-9.
120DEThe effect of alclometasone dipropionate cream 0.05% on the hypothalamic-pituitary-adrenal axis of normal volunteers. * Thornfeldt C, * Cornell RC, * Stoughton RB. J Int Med Res. 1985;13(5):276-80
121DEParticipation of CYP2C8 in retinoic acid 4-hydroxylation in human hepatic microsomes. * Nadin L, * Murray M.Biochem Pharmacol. 1999 Oct 1;58(7):1201-8
122DEIn vitro metabolism of clindamycin in human liver and intestinal microsomes. * Wynalda MA, * Hutzler JM, * Koets MD, * Podoll T, * Wienkers LC. Drug Metab Dispos. 2003 Jul;31(7):878-87
123DEInhibitory effects of pomelo on the metabolism of tacrolimus and the activities of CYP3A4 and P-glycoprotein. * Egashira K, * Ohtani H, * Itoh S, * Koyabu N, * Tsujimoto M, * Murakami H, * Sawada Y. Drug Metab Dispos. 2004 Aug;32(8):828-33
124DEIdentification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride. * Huskey SW, * Dean DC, * Miller RR, * Rasmusson GH, * Chiu SH. Drug Metab Dispos. 1995 Oct;23(10):1126-35.
125DEPimecrolimus: absorption, distribution, metabolism, and excretion in healthy volunteers after a single oral dose and supplementary investigations in vitro. * Zollinger M, * Waldmeier F, * Hartmann S, * Zenke G, * Zimmerlin AG, * Glaenzel U, * Baldeck JP, * Schweitzer A, * Berthier S, * Moenius T, * Grassberger MA. Drug Metab Dispos. 2006 May;34(5):765-74. Epub 2006 Feb 7
126DEMode of action of anti-Candida drugs: focus on terconazole and other ergosterol biosynthesis inhibitors. * Vanden Bossche H, * Marichal P.Am J Obstet Gynecol. 1991 Oct;165(4 Pt 2):1193-9
127DEConversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19. * Hirani VN, * Raucy JL, * Lasker JM. Drug Metab Dispos. 2004 Dec;32(12):1462-7. Epub 2004 Sep 24
128DEPharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. * Haas DW, * Smeaton LM, * Shafer RW, * Robbins GK, * Morse GD, * Labbe L, * Wilkinson GR, * Clifford DB, * D'Aquila RT, * De Gruttola V, * Pollard RB, * Merigan TC, * Hirsch MS, * George AL Jr, * Donahue JP, * Kim RB. J Infect Dis. 2005 Dec 1;192(11):1931-42. Epub 2005 Nov 1.
129DEInfluence of goldenseal root on the pharmacokinetics of indinavir. * Sandhu RS, * Prescilla RP, * Simonelli TM, * Edwards DJ. J Clin Pharmacol. 2003 Nov;43(11):1283-8
130DEDelavirdine: clinical pharmacokinetics and drug interactions. * Tran JQ, * Gerber JG, * Kerr BM.Clin Pharmacokinet. 2001;40(3):207-26
131DEPotent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction. * Kumar GN, * Dykstra J, * Roberts EM, * Jayanti VK, * Hickman D, * Uchic J, * Yao Y, * Surber B, * Thomas S, * Granneman GR.Drug Metab Dispos. 1999 Aug;27(8):902-8
132DEVirtual screening and prediction of site of metabolism for cytochrome P450 1A2 ligands,* Vasanthanathan P,* Hritz J, * Taboureau O, * Olsen L, * Steen Jørgensen F, * Vermeulen NP, *Oostenbrink C, J Chem Inf Model. 2008 Dec 19.